Serial EUS-Guided FNA for the Surveillance of Pancreatic Cysts: A Study of Long-Term Performance of Tumor Markers

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2022 Mar 1

PMID 35229208

Authors

Mahmoud A Rahal

John M DeWitt

Harsh Patel

C Max Schmidt

Eugene P Ceppa

Rachel E Simpson

Stuart Sherman

Mohammad Al-Haddad

Affiliations

Soon will be listed here.

Abstract

Background And Aim: The natural history of KRAS mutations in mucinous pancreatic cysts (MPCs) over time remains to be fully understood. The aim of this study was to examine the performance of DNA markers and assess changes of KRAS mutations over time.

Methods: Patients who underwent EUS-FNA of pancreatic cysts with at least two separate molecular analysis results were included in the study. We assessed the baseline patient and cyst characteristics, and DNA fluid analysis. The presence of either a KRAS mutation, or a CEA > 192 ng/ml was used as the diagnostic standard for mucinous cysts when surgical pathology was not available.

Results: A total of 933 pancreatic cyst fluid samples were collected, including 117 with ≥ 2 FNAs. Examinations were performed over a median of 30 months (range 1-115 months). Forty-three (36%) had a mutant KRAS on the index analysis out of which 26 had a change in their KRAS status to the wild-type. Eighty-one (64%) had a wild-type KRAS on the index analysis out of which 18 had change in their KRAS status to mutant type. There was no significant difference in the index cyst characteristics, presence of symptoms, or main duct involvement based on KRAS status change. Increasing age was associated with a changing KRAS mutation status (p = 0.023).

Conclusion: KRAS mutations gain and loss in pancreatic cyst fluid appears to occur frequently during long-term surveillance of MPCs. Age appears to be the only predictor for KRAS change over time.

Citing Articles

Clinical trajectory of intraductal papillary mucinous neoplasms progressing to pancreatic carcinomas during long-term surveillance: a prospective series of 100 carcinoma cases.

Oyama H, Hamada T, Nakai Y, Tanaka M, Endo G, Hakuta R J Gastroenterol. 2023; 58(10):1068-1080.

PMID: 37507590 PMC: 10522754. DOI: 10.1007/s00535-023-02028-0.

Modern aspects of the management of pancreatic intraductal papillary mucinous neoplasms: a narrative review.

Pavlidis E, Sapalidis K, Pavlidis T Rom J Morphol Embryol. 2023; 63(3):491-502.

PMID: 36588487 PMC: 9926151. DOI: 10.47162/RJME.63.3.03.

References

Omori Y, Ono Y, Tanino M, Karasaki H, Yamaguchi H, Furukawa T . Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. Gastroenterology. 2018; 156(3):647-661.e2. DOI: 10.1053/j.gastro.2018.10.029. View

Al-Haddad M, Kowalski T, Siddiqui A, Mertz H, Mallat D, Haddad N . Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy. 2014; 47(2):136-42. DOI: 10.1055/s-0034-1390742. View

Spindler K, Pallisgaard N, Andersen R, Jakobsen A . Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer. 2014; 135(9):2215-22. DOI: 10.1002/ijc.28863. View

. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018; 67(5):789-804. PMC: 5890653. DOI: 10.1136/gutjnl-2018-316027. View

Vege S, Ziring B, Jain R, Moayyedi P . American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015; 148(4):819-22. DOI: 10.1053/j.gastro.2015.01.015. View

Singhi A, McGrath K, Brand R, Khalid A, Zeh H, Chennat J . Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. Gut. 2017; 67(12):2131-2141. PMC: 6241612. DOI: 10.1136/gutjnl-2016-313586. View

Collins M, Bednar F, Zhang Y, Brisset J, Galban S, Galban C . Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest. 2012; 122(2):639-53. PMC: 3266788. DOI: 10.1172/JCI59227. View

Nikiforova M, Khalid A, Fasanella K, McGrath K, Brand R, Chennat J . Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. Mod Pathol. 2013; 26(11):1478-87. DOI: 10.1038/modpathol.2013.91. View

Winner M, Sethi A, Poneros J, Stavropoulos S, Francisco P, Lightdale C . The role of molecular analysis in the diagnosis and surveillance of pancreatic cystic neoplasms. JOP. 2015; 16(2):143-9. DOI: 10.6092/1590-8577/2941. View

10.

Khalid A, Zahid M, Finkelstein S, LeBlanc J, Kaushik N, Ahmad N . Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc. 2009; 69(6):1095-102. DOI: 10.1016/j.gie.2008.07.033. View

11.

Fischer C, Beleva Guthrie V, Braxton A, Zheng L, Wang P, Song Q . Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations. Gastroenterology. 2019; 157(4):1123-1137.e22. PMC: 6756950. DOI: 10.1053/j.gastro.2019.06.001. View

12.

El Chafic A, El Hajj I, DeWitt J, Schmidt C, Siddiqui A, Sherman S . Does cyst growth predict malignancy in branch duct intraductal papillary mucinous neoplasms? Results of a large multicenter experience. Dig Liver Dis. 2018; 50(9):961-968. DOI: 10.1016/j.dld.2018.04.022. View

13.

Al-Haddad M, DeWitt J, Sherman S, Schmidt C, LeBlanc J, McHenry L . Performance characteristics of molecular (DNA) analysis for the diagnosis of mucinous pancreatic cysts. Gastrointest Endosc. 2013; 79(1):79-87. DOI: 10.1016/j.gie.2013.05.026. View

14.

Shibata H, Ohike N, Norose T, Isobe T, Suzuki R, Imai H . Mucinous Cystic Neoplasms Lined by Abundant Mucinous Epithelium Frequently Involve KRAS Mutations and Malignant Progression. Anticancer Res. 2017; 37(12):7063-7068. DOI: 10.21873/anticanres.12178. View

15.

Khalid A, McGrath K, Zahid M, Wilson M, Brody D, Swalsky P . The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol. 2005; 3(10):967-73. DOI: 10.1016/s1542-3565(05)00409-x. View

16.

Nakai Y, Iwashita T, Shinoura S, Park D, Samarasena J, Lee J . Role of serial EUS-guided FNA on pancreatic cystic neoplasms: a retrospective analysis of repeat carcinoembryonic antigen measurements. Gastrointest Endosc. 2016; 84(5):780-784. PMC: 5926180. DOI: 10.1016/j.gie.2016.03.1500. View

17.

Valsangkar N, Morales-Oyarvide V, Thayer S, Ferrone C, Wargo J, Warshaw A . 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery. 2012; 152(3 Suppl 1):S4-12. PMC: 3806101. DOI: 10.1016/j.surg.2012.05.033. View

18.

Faias S, Duarte M, Albuquerque C, Pereira da Silva J, Fonseca R, Roque R . Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA. Dig Dis Sci. 2018; 63(9):2351-2361. DOI: 10.1007/s10620-018-5128-y. View

19.

de Biase D, Visani M, Baccarini P, Polifemo A, Maimone A, Fornelli A . Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. PLoS One. 2014; 9(2):e87651. PMC: 3913642. DOI: 10.1371/journal.pone.0087651. View

20.

Elta G, Enestvedt B, Sauer B, Lennon A . ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol. 2018; 113(4):464-479. DOI: 10.1038/ajg.2018.14. View